Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy-Reference-Cited by-同舟云学术

Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy

Published:2019-07-19 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Guo Yadong,Mao Shiyu,Zhang Aihong,Zhang Junfeng,Wang Longsheng,Wang Ruiliang,Zhang Wentao,Zhang Ziwei,Wu Yuan,Cao Xuan,Yang Bin,Yao Xudong

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference25 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin.,2018

2. Prostate cancer, version 1 2016;Mohler;J Natl Compr Canc Netw.,2016

3. Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017;Gillessen;Eur Urol.,2018

4. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer;Morris;Int J Radiat Oncol Biol Phys.,2017

5. Survival outcomes of dose-escalated external beam radiotherapy versus combined brachytherapy for intermediate and high risk prostate cancer using the national cancer data base;Amini;J Urol.,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients;Journal of Robotic Surgery;2023-07-19

2. Diagnosis of high-grade prostate cancer in patients with unexpectedly low prostate specific antigen levels: a rare case series;Bali Medical Journal;2023-05-29

3. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer;Life;2023-04-23

4. Raised prostate-specific antigen alone may not be a true predictor in high-risk prostate cancer: A retrospective cohort analysis;Indian Journal of Urology;2022

5. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population‐based study;Cancer Medicine;2021-06-29